Pacira BioSciences

Forecast & Rating9 analysts currently cover Pacira BioSciences, with about 11.1% giving a positive rating — meaning they expect the stock to rise. The average price target is $33.57, about 7.6% downside from the current price of $36.35. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 38.7% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on Pacira BioSciences's outlook. Data as of Oct 9, 2026; for reference only and not investment advice.